On 3 February 2025, the European Commission (“EC”) published an updated version of its frequently asked questions (“FAQs”) on the EU Data Act.[1] The Data Act, which is intended to make data more accessible to users of IoT devices
As a senior in high school, I must make a lot of decisions for the next steps in my life. The questions people always have for me these days are; “How is senior year going?” “Do you know what you
Shareholder oppression, or minority shareholder oppression, is generally thought to occur when the majority shareholders misuse their power to oppress or control the minority. The classes of conduct that give rise to a remedy for shareholder oppression are not closed,
On February 4, 2025, HyClone Laboratories, LLC (“HyClone”), a cell culture media supplier, filed a Motion to Quash a subpoena issued by Amgen, Inc. (“Amgen”). The underlying subpoena was issued in Amgen’s ongoing denosumab BPCIA litigation against Fresenius Kabi USA,
Seyfarth’s Trademark practice earned widespread recognition in the 2025 edition of the World Trademark Review 1000 spotlighting “world-class legal trademark expertise.” The firm earned high rankings nationally as well as in the states of California, Georgia, Illinois, and New York.
On January 27, 2025, the Federal Circuit held that the Patent Trial and Appeal Board (“PTAB”) “has jurisdiction over IPRs concerning expired patents.” See Apple Inc. v. Gesture Tech. Partners, LLC, 2025 WL 299939, *2 (Fed. Cir. Jan. 27, 2025).
My favorite blog post of the year—where I get to assess the best commercials, track the rise in ad costs, and challenge you to identify your favorite celebrity endorsement.
This year, demand for ad space was “robust” with some 30-second
SHEIN and TEMU are Chinese online retail platforms known for selling a wide range of consumer goods like clothing, accessories, and home products at low prices.
The de minimis tariff exception refers to a rule that allows small-value imports to
A motivational passage from Keith Bell’s book, Winning Isn’t Normal, sparks a legal battle after Ole Miss coach Lane Kiffin shares it on Twitter. Scott Hervey and Tara Sattler dive into the lawsuit, exploring how the Fifth Circuit’s ruling
CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars: On January 30, 2025, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions recommending the grant of marketing authorizations for three biosimilar products—Amgen’s PAVBLU and SKOJOY, and